

ASX ANNOUNCEMENT

Results of the Annual General Meeting Held on Thursday 14 November 2013

Sydney, Australia, 14 November 2013: In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution on the agenda of this morning's Annual General Meeting.

Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
15,554,495	12,478,429	375,133	49,396

The motion was carried as an ordinary resolution on a show of hands.

Election of Director - Mr Kevin Buchi

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
17,432,025	12,040,641	79,642	50,985

The motion was carried as an ordinary resolution on a show of hands.

Re-election of Director – Dr John Chiplin

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
17,449,592	12,040,641	62,075	50,985

The motion was carried as an ordinary resolution on a show of hands.

Re-election of Director – Mr Iain Ross

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
17,444,948	12,040,641	66,719	50,985

The motion was carried as an ordinary resolution on a show of hands.

Approval Of Placement Facility

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
16,813,106	12,040,748	735,305	14,134

The motion was carried as a special resolution on a show of hands.

Increase In Non-Executive Directors' Fees

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
15,415,237	6,811,966	950,513	51,491

The motion was carried as an ordinary resolution on a show of hands.

Issue Of Options To Director – Mr Kevin Buchi

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
15,531,963	6,811,966	787,285	97,993

The motion was carried as an ordinary resolution on a show of hands.

Ratification Of Prior Issue Of Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
16,993,221	12,469,715	134,637	5,720

The motion was carried as an ordinary resolution on a show of hands.

For more information please contact: Greg West | Company Secretary
Phone: +61 (02) 9555 6986 | gwest@benitec.com | www.benitec.com

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.